Evan Dellon, MD, MPH, is a professor in the division of gastroenterology and hepatology and director of the Center for Esophageal Diseases and Swallowing at UNC School of Medicine.

Joy Chang, MD, MS, is an assistant professor of medicine in the division of gastroenterology at the University of Michigan in Ann Arbor.

This episode, titled ‘Long-Term Budesonide Oral Suspension Therapy in EoE,’ features panelists reviewing extended data with budesonide oral suspension and discussing what the findings may mean for long-term management. The experts describe outcomes from a study extending to 48 months, including histologic response using both stringent and conventional eosinophil thresholds and sustained improvement in EoE Endoscopic Reference Score.

Long-Term Budesonide Oral Suspension Therapy in EoE

The panel also discusses the practical reality of long-term swallowed corticosteroid use. Some patients in the study underwent dose reductions, while most maintained their dose. Faculty stress that prescribed dosing and actual patient use are not always identical, particularly with a treatment that may require twice-daily administration. They describe documenting what patients are actually taking rather than assuming perfect adherence from the prescription alone.

Safety and tolerability are also reviewed. Treatment-emergent adverse events occurred in many participants, although most were not considered related to therapy. Esophageal candidiasis is highlighted as an important but generally treatable adverse event, with recurrent candidiasis occasionally limiting continued therapy. Overall, the panel interprets the extension findings as evidence that a substantial proportion of patients can achieve and maintain histologic and endoscopic response over the long term with swallowed budesonide therapy.

In the next episode, ‘Individualizing EoE Treatment Across the Age Spectrum,’ panelists will examine how efficacy, safety, treatment feasibility, patient preferences, and pediatric evidence inform shared decision-making.

Videos

Long-term EoE control depends on both sustained response and a treatment patients can realistically maintain. Extended BOS data provide insight into histologic remission, endoscopic improvement, and tolerability over several years.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Video Series

Muthiah Vaduganathan, MD, MPH, is a cardiologist specializing in cardiorenal metabolism at Brigham and Women's Hospital in Boston, MA. Vaduganathan is a member of Practical Cardiology's advisory board and co-host of Don't Miss a Beat, a podcast presented by Inside Cardiology.

Stephen Greene, MD, is an associate professor of medicine at Duke University School of Medicine and cardiologist at the Duke Clinical Research Institute in Durham, NC. Greene is a member of HCPLive's advisory board and co-host of Don't Miss a Beat, a podcast presented by Inside Cardiology.

Topline announcements had set expectations heading into the 

American Heart Association (AHA) Scientific Sessions 2026

, and the full Lp(a)HORIZON and ZEUS data presented in Chicago filled in the rest of the story. Pelacarsen and ziltivekimab each lowered their targets, lipoprotein(a) [Lp(a)] and interleukin-6 (IL-6), by wide margins, yet neither reduced major adverse cardiovascular events (MACE) in 

On this episode of Don't Miss a Beat, recorded at the AHA Scientific Sessions 2026 in Chicago, Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, discuss 2 closely watched outcomes trials testing lipoprotein(a) lowering and interleukin-6 inhibition in atherosclerotic disease. They talk through how the results fit with decades of genetic evidence and where research on these pathways goes next.

Don't Miss a Beat: What Lp(a)HORIZON and ZEUS Teach About Clinical Trial Science

On a recent episode of Don't Miss a Beat, hosts Stephen Greene, MD, of Duke University School of Medicine, and Muthiah Vaduganathan, MD, MPH, of Brigham and Women's Hospital, discussed both trials from Chicago. Their conversation centered on why well-designed studies built on decades of genetic and epidemiologic evidence fell short.

Lp(a)HORIZON randomized 8350 patients with established ASCVD and an Lp(a) level of at least 70 mg/dL to monthly pelacarsen 80 mg or placebo.

 ZEUS randomized 6376 patients with ASCVD, chronic kidney disease (CKD), and a high-sensitivity C-reactive protein (hsCRP) level of at least 2 mg/L to monthly ziltivekimab 15 mg or placebo.

Each agent lowered its target by roughly 70% to 80%, yet MACE was unchanged with pelacarsen (HR, 1.02; 95% CI, 0.90-1.15; P = .76) and ziltivekimab (HR, 0.99; 95% CI, 0.88-1.11; 

 On-treatment and achieved-level analyses also showed no benefit, ruling out drug discontinuation as the explanation. Serious infections were modestly more frequent with ziltivekimab (20.4% vs 17.9%), though not enough to offset meaningful benefit.

Several hypotheses may explain the disconnect. Mendelian randomization data reflect lifelong low exposure from birth, whereas these trials intervened late in life, in patients with established disease already on statins and other standard therapies.

Potent LDL cholesterol lowering may also saturate a final common atherosclerotic pathway, limiting further gains from Lp(a) reduction. In ZEUS, CKD-driven, nonatherosclerotic mechanisms may have dominated residual risk, and the degree of lowering needed for clinical benefit remains unknown.

Ongoing programs should help separate population effects from drug effects. Ziltivekimab trials in heart failure with preserved ejection fraction, HERMES and ATHENA, were stopped early, while ARTEMIS continues to test the agent soon after acute myocardial infarction, when inflammation peaks. Additional Lp(a)-lowering agents are being tested in lower-risk primary prevention populations.

Collectively, the results deliver definitive answers at the tested doses and degrees of target engagement, unlike the borderline or underpowered findings common in cardiovascular research. With positive signals from CANTOS and colchicine trials still standing, success in both pathways will likely hinge on precise selection of patients, timing, and magnitude of lowering.

Cho L, Nicholls SJ, Frndak S, et al. Pelacarsen and cardiovascular outcomes in patients with high lipoprotein(a). 

Ridker PM, Lincoff AM, Marx N, et al. Interleukin-6 inhibition with ziltivekimab for atherosclerotic disease. 

Podcasts

Lp(a)HORIZON and ZEUS hit their biomarker targets but not MACE. Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, unpack both at AHA 2026.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Don’t Miss a Beat

The Don't Miss a Beat podcast breaks down the latest evidence and clinical trial insights across cardiovascular, renal, and metabolic diseases. Don’t Miss a Beat as Steve Greene, MD, and Muthu Vaduganathan, MD, MPH, critically examine recent advances in clinical care and research with perspectives from global experts in the field.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Dyslipidemia

Atherosclerotic Cardiovascular Disease

Luke Laffin, MD, is the co-director of the Center for Blood Pressure Disorders, medical director of cardiac rehabilitation, and associate professor of medicine at Cleveland Clinic.

Long-term lorundrostat treatment has resulted in sustained blood pressure control with an adequate safety profile among patients with 

, according to the open-label extension study Transform-HTN.

Transform-HTN: Lorundrostat Maintains Blood Pressure Reductions in Open-Label Extension 

 in Chicago, Illinois, by Luke Laffin, MD, a preventive cardiologist, co-director of the Center for Blood Pressure Disorders, and Medical Director of C5Research at Cleveland Clinic and an associate professor of medicine at the Cleveland Clinic Lerner College of Medicine.

“I think we now understand better that people who take lorundrostat maintain blood pressure reductions throughout this open-label extension period,” Laffin told 

 in an exclusive interview. “I think these data clearly make the case for aldosterone’s role in uncontrolled hypertension, because we also paired it with biomarkers that show aldosterone essentially staying lower throughout the treatment course with lorundrostat.”

Lorundrostat, an investigational aldosterone synthase inhibitor (ASI) in development by Mineralys Therapeutics, demonstrated its blood pressure-lowering capacity in the 12-week, randomized, double-blind, placebo-controlled Launch-HTN trial. Briefly, Launch-HTN enrolled patients with uncontrolled hypertension, including treatment-resistant hypertension, and randomly assigned them in a 1:2:1 ratio to 50 mg of lorundrostat daily for 6 weeks followed by 100 mg of lorundrostat for 6 weeks if certain criteria were met, or to 50 mg of lorundrostat or matching placebo daily for 12 weeks.

A total of 1083 patients were enrolled in Launch-HTN, with a mean age of 61.6 years. The pooled 50 mg group, encompassing 808 patients, saw a least-squares mean change in automated office systolic blood pressure of -16.9 mmHg (95% CI, -19 to -14.9) at week 6 versus -7.9 mmHg (95% CI, -11.5 to -4.2) for placebo (least-squares mean difference, -9.1 mmHg [95% CI, -13.3 to -4.9]; 

 <.001). Treatment-emergent adverse events occurred in 49.9% of patients and were mostly mild or moderate.

For Transform-HTN, Laffin and colleagues included patients who had completed 12 weeks of lorundrostat treatment in the Launch-HTN trial. The primary endpoint was change in automated office systolic blood pressure from baseline to week 48. Safety outcomes included treatment-emergent adverse events, as well as adverse events of interest, which included dose modification for hyperkalemia, hyponatremia, and reductions in kidney function.

Of the 808 patients enrolled in Launch-HTN, 632 continued into the open-label extension. Of these patients, 549 completed 48 weeks of treatment, and 583 completed 48 weeks of follow-up. Mean age among this population was 61 years, and mean body mass index (BMI) was 33 kg/m2. Mean baseline blood pressure was 149/87 mmHg, and 59% of patients were taking ≥3 antihypertensive medications.

By week 48, Laffin and colleagues noted a least-squares mean change in automated office systolic blood pressure of -17.8 mmHg (95% CI, -19.6 to -16; 

 <.0001). Additionally, automated office systolic blood pressure was achieved by 24.6%, 56%, and 77.9% of patients, respectively. Mean change in automated office diastolic blood pressure at week 48 was -9.2 mmHg (95% CI, -10.2 to -8.3; 

 <.0001). The team also found that serum potassium >6 mmol/L occurred in only 2.5% of patients over the 36-week open-label treatment period.

Laffin and colleagues ultimately concluded that these data reflect sustained blood pressure control over a long period of lorundrostat treatment, indicating its long-term efficacy. Additionally, its acceptable safety profile from Launch-HTN was echoed in Transform-HTN, positioning it as a safe and tolerable treatment in this population.

Laffin also discussed his thoughts on lorundrostat’s future, should it receive regulatory approval. He addressed its position in a field largely dominated by spironolactone, another very effective treatment in this patient population.

“Spironolactone intolerance isn’t uncommon. I use a lot of spironolactone in my practice because they’re approved, they’re good drugs, and they work for resistant hypertension,” Laffin said. “But patients will come in with all these side effects, and they need to be switched to an ASI. Unfortunately, we don’t have direct comparative evidence against spironolactone with lorundrostat – hopefully, at some point in the future, we will.”

Editors’ Note: Laffin reports relevant disclosures with AstraZeneca, Arrowhead, Medtronic, Eli Lilly, Mineralys, Crispr Therapeutics, Novartis, Novo Nordisk, and others.

Saxena M, Rodman D, Borghi C, et al. Transform-HTN: Long-Term Efficacy and Safety of Lorundrostat, a Novel Aldosterone Synthase Inhibitor, in Uncontrolled Hypertension. Presented at the American Heart Association (AHA) Scientific Sessions 2026, Chicago, IL. November 6-9, 2026.

Saxena M, Laffin L, Borghi C, et al. Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension. 

Luke Laffin, MD, discusses the open-label extension from Launch-HTN, which further investigated the efficacy of lorundrostat in uncontrolled hypertension.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Waldman Professor of Dermatology and Immunology, health system chair of the Kimberly and Eric J. Waldman Department of Dermatology, and director of the Laboratory for Inflammatory Skin Diseases at the Icahn School of Medicine at Mount Sina

 report inadequately controlled disease despite current biologics targeting type 2 inflammation.

 Oral JAK inhibitors act on broader pathways but carry a boxed warning many patients and dermatologists prefer to avoid. Rezpegaldesleukin is an IL-2 receptor agonist designed to selectively expand regulatory T cells (Tregs) rather than block a single cytokine axis.

In the phase 2b REZOLVE-AD trial (NCT06136741), rezpegaldesleukin 24 μg/kg every 2 weeks produced statistically significant improvements across primary and secondary endpoints after a 16-week induction phase compared with placebo.

 A biomarker sub-study presented as a late-breaking oral at EADV Congress 2026 analyzed 100 patients, 59 on rezpegaldesleukin and 41 on placebo. Blood and lesional tape strips were collected at baseline and at weeks 2 and 4 and evaluated by RNA-seq and Olink proteomics.

By week 2, rezpegaldesleukin significantly upregulated Treg and T-cell activation markers, including ICOS, CD3D/E, CTLA4, FOXP3, IL2RA, and IL2RB, versus both baseline and placebo.

<.0001) each predicted week 16 EASI exclusively in the rezpegaldesleukin arm, with no comparable correlations in the placebo arm (all |R|≤0.30, 

Rezpegaldesleukin also reduced fibrosis-associated transcripts, including POSTN, COL15A1, ELN, COL16A1, COL1A1, and LUM, alongside markers across the Th1, Th2, Th17, and Th22 axes (all P<0.05).

 Clinically, the mean EASI reduction reached 64.3% at week 16, with 42.4% of patients achieving EASI75 and significant separation from placebo as early as week 2 across EASI-50/75/90, IGA 0/1, and itch outcomes.

Emma Guttman-Yassky, MD, PhD, Waldman Professor of Dermatology and Immunology at the Icahn School of Medicine at Mount Sinai, led the biomarker sub-study. In the following interview, Guttman-Yassky discusses how rezpegaldesleukin's regulatory T-cell mechanism differs from existing AD therapies and what the earliest molecular changes revealed.

HCPLive: Despite biologics and JAK inhibitors, why do so many AD patients still have uncontrolled disease?

Atopic dermatitis is a heterogeneous disease, and while we have good treatments now, they either target one pathway, like the Th2 pathway, or they're oral JAK inhibitors that act on more pathways. The issue with oral medications, particularly JAK inhibitors, is the black box warning, so many dermatologists and many patients don't want to go there. When we give patients Th2-targeting biologics, we will miss some patients because of the heterogeneity of the disease.

HCPLive: IL-2 can stimulate both regulatory and effector T cells. How is this molecule designed to favor Tregs?

It's all about the dosing. The dosing is key here. We did the biomarker study, and interestingly, the biomarkers showed even greater differentiation from placebo, because typically, when you look at the skin, it tells you things earlier than the clinical results, and we saw things much, much earlier. In fact, even at week 2 we saw meaningful data, and based on week 2 biomarkers, we could predict week 16 responses.

HCPLive: Can you expand on what the skin showed at the molecular level within the first 2 weeks?

We saw significant modulation of many markers, including Th2 markers. We also saw increases in some Treg markers, and some of these, such as CCL17 and Treg markers like TGF-beta and IL-10, were significantly correlated with the clinical improvement at week 16.

[Fibrosis-associated markers also fell, which] matters because in atopic dermatitis you have hyperplasia, and hyperplasia involves some fibrosis. We also know fibroblasts can produce inflammatory markers and are important. In general, we believe fibrosis is important in atopic dermatitis and in other diseases, so we're excited about the potential of this drug for other indications.

HCPLive: Blood markers at week 2 tracked with EASI at week 16. Do you see potential there for predicting response?

Yes, we think that's a very nice feature that we sometimes see, where early responses can predict later responses, and I can see how this could shorten trials in the future and save money.

HCPLive: Is there anything else from the EADV data you think is important to know?

Just that, interestingly, when you look at the clinical data, you saw large placebo responses, but when you looked at the biomarker data, you saw much smaller placebo responses. This is the amazing thing about biomarkers: they're objective, and for companies it's important to do this, because it can increase the delta between your drug and placebo and really get that differentiation.

HCPLive: Looking forward, what would you want to learn from phase 3 studies, and does the same biology apply to alopecia?

We also looked at pathways relevant to alopecia, and we saw they were modulated. I'm very excited about alopecia and this drug. I'd also like to learn what happens when you stop the drug after a year, or after prolonged use, and see when the disease actually comes back. Maybe it will take some time.

Editor's Note: This transcript has been edited for grammar and clarity using artificial intelligence tools.

Silverberg JI, Guttman-Yassky E, et al. REZOLVE-AD: 16-week induction results of rezpegaldesleukin in moderate-to-severe atopic dermatitis. Lancet. Published online August 25, 2026. doi:10.1016/S0140-6736(26)01143-8

Manson M, Manzo Margiotta F, Del Duca E, et al. Multi-omic profiling identifies early molecular responses to rezpegaldesleukin, a novel regulatory T cell-inducing therapy, in atopic dermatitis [abstract LB-219]. Presented at: EADV Congress 2026; September 30-October 3, 2026; Vienna, Austria.

Articles

Emma Guttman-Yassky, MD, discusses biomarker data showing rezpegaldesleukin's regulatory T-cell mechanism separates from placebo early.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Rezpegaldesleukin's Early Treg Signal in AD: Emma Guttman-Yassky, MD

Michelle O'Donoghue, MD, is the McGillycuddy-Logue Endowed Chair in Cardiology at Brigham and Women's Hospital and associate professor at Harvard Medical School

MAR001’s inhibition of ANGPTL4 substantially reduced fasting triglyceride (TG) levels in patients with 

 and remnant cholesterol (RC), according to new data from Part A of the TYDAL-TIMI 78 trial.

TYDAL-TIMI 78: MAR001 Reduces Fasting Triglyceride Through ANGPTL4 Inhibition

 in Chicago, Illinois, by Michelle O’Donoghue, MD, the McGillycuddy-Logue Distinguished Chair in Cardiology at Brigham and Women’s Hospital, an associate professor of medicine at Harvard Medical School, and the senior investigator in the TIMI study group.

“We know that, with the growing prevalence of obesity, diabetes, and many other disease states that track along with having higher triglycerides, that the prevalence of hypertriglyceridemia is also growing for a variety of reasons,” O’Donoghue told 

 in an exclusive interview. “But it has been a tough nut to crack in terms of finding therapies that are both effective for lowering triglycerides and that lower risk of cardiovascular events.”

TYDAL-TIMI 78 is a 2-part phase 2b, randomized, double-blind, parallel-group, placebo-controlled study comparing MAR001 to placebo. Patients with elevated fasting or non-fasting TGs and RC, as well as a fasting LDL-C ≥50 mg/dL and ≤130 mg/dL, among other criteria, were eligible for enrollment in Part A of the trial. Patients with acute or chronic liver disease, a history of type 1 diabetes mellitus or diabetic ketoacidosis, or TG concentration ≥880 mg/dL, among other criteria, were excluded.

Enrolled patients were randomly assigned in a 1:1:1:1 ratio to receive either MAR001 300 mg, 450 mg, or 900 mg or matching placebo, administered subcutaneously over 24 weeks. The primary endpoint was percent change from baseline in fasting TG levels at week 12. Secondary endpoints included percent change in fasting RC at week 12, percentage of non-fasting TG at week 16, and the proportion of patients with baseline TG ≥150 mg/dL achieving TG <150 mg/dL at week 12, among others.

O’Donoghue and colleagues enrolled 236 patients in the trial, with 177 assigned to receive MAR001 and 59 to receive placebo. Of these patients, 235 received ≥1 dose and were included in the primary efficacy analyses. Mean age among all patients was 60.4 years, and the median TG level at baseline was 249.5 mg/dL (interquartile range [IQR], 210 to 313).

By week 12, the least-squares mean percent changes from baseline in fasting TG were -33.9% in the 300 mg arm, -35.7% in the 450 mg arm, and -40.3% in the 900 mg arm, compared with 5.2% in the placebo arm. The corresponding placebo-adjusted least-squares mean percent changes were -39.1 percentage points (95% CI, -46.8 to -31.5), -40.9 percentage points (95% CI, -48.7 to -33.1), and -45.5 percentage points (95% CI, -53.2 to -37.8), respectively (

 <.001 for all comparisons). Adverse events occurred in 123 of 177 (69%) patients in the pooled MAR001 group versus 45 of 58 (78%) patients in the placebo group.

O’Donoghue and colleagues concluded that inhibition of ANGPTL4 with MAR001 significantly reduced fasting TG levels, with the magnitude of lowering appearing more pronounced among patients with higher baseline levels. Additionally, treatment did not lead to adverse changes in aminotransferase levels or glucose homeostasis markers.

“So ultimately, some degree of effect modification was observed, and that has helped to set the stage for the phase B that is now launching for that program,” O’Donoghue said. “That is specifically looking at, and will be enrolling, patients who have severe forms of hypertriglyceridemia.”

Editors’ Note: O’Donoghue reports disclosures with Amgen, Eli Lilly, Janssen, Novartis, Novo Nordisk, Verve, and others.

O’Donoghue ML, Juliano RA, Yi BA, et al. ANGPTL4 inhibition in adults with elevated triglyceride levels. New England Journal of Medicine. Published online November 9, 2026. 

Marea Therapeutics. Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol (TYDAL-TIMI 78). ClinicalTrials.gov Identifier: NCT07028749. Updated September 2, 2026. Accessed November 10, 2026. 

https://clinicaltrials.gov/study/NCT07028749

Michelle O’Donoghue, MD, discusses the results of Part A of the TYDAL-TIMI 78 trial, demonstrating MAR001’s comparative efficacy to placebo.

The most effective EoE therapy is one that controls disease and fits the patient's life. Age, caregiver involvement, treatment feasibility, efficacy, and safety all shape individualized treatment decisions.

Individualizing EoE Treatment Across the Age Spectrum

Late-breaking ELSPIRE data show elafibranor normalized ALP in 85% of patients with PBC and ALP below 1.67 times ULN despite UDCA, vs 23% with placebo.

Hepatology

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

ELSPIRE: Elafibranor Normalizes ALP in PBC Below the 1.67 Threshold

Liver stiffness, bilirubin, and symptoms can guide when to start second-line PBC therapy as ALP normalization becomes achievable for more patients.

When to Start Second-Line Therapy in PBC, With Kris Kowdley, MD

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for 

. He is also the executive producer of two podcasts: 

. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Risankizumab improved skin clearance, itch, and quality of life through 52 weeks in pediatric psoriasis in the phase 3 OptIMMize-1 study.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

OptIMMize-1: Risankizumab Clears Skin in Children, Teens with Psoriasis

David Singh, MBBChir, MA (Cantab), MRCP, MD, FBPhS, FERS, is a professor of Clinical Pharmacology & Respiratory Medicine at the University of Manchester and is the medical director of the Medicines Evaluation Unit (MEU).

Dave Singh, MD, discusses IL-33 inhibition for non-type 2 COPD, 2027 GOLD report refinements, and how to view biologics not yet in the GOLD algorithm.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

IL-33 Biologics and the 2027 GOLD Report, With Dave Singh, MD

In 3-year BE HEARD data, close to half of bimekizumab-treated HS patients reported no quality-of-life impact, regardless of baseline draining tunnel count.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

3-Year BE HEARD Data Link Bimekizumab to Fewer HS Draining Tunnels

Autumn Burnette, MD, FACAAI, a clinical allergist physician at Howard University.

Autumn Burnette, MD, hosts a new monthly allergy and immunology podcast from HCPLive, opening with an episode on hereditary angioedema.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Allergy Rounds With Dr. Autumn

Allergy Rounds is a monthly podcast where Autumn Burnette, MD, of Howard University makes the rounds with allergists, pulmonologists, dermatologists, and other specialists to discuss what’s new, from emerging HAE therapies and gene-editing research to newly approved triple therapies and the payer battles that stand between patients and treatment. Each episode goes past the press release to ask what a new approval, trial result, or guideline shift actually means for the clinician deciding what to prescribe next week.

Martina J. Porter, MD, is a dermatologist at Beth Israel Deaconess Medical Center.

Martina Porter, MD, of Beth Israel Deaconess Medical Center discusses unmet needs in HS and where oral povorcitinib fits among emerging options.

Rheumatology Winter Clinical Symposium

Unmet Needs in HS and Emerging Oral Options, With Martina Porter, MD

Scientific Affairs, Innovation, and New Technology

MAESTRO-NASH data show early liver fat reductions on MRI-PDFF predict biopsy-confirmed MASH resolution and fibrosis improvement with resmetirom.

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Early Liver Fat Changes Predict Resmetirom Response in MASH

Mazen Noureddin, MD, MHSc, is a professor of medicine and a transplant hepatologist at Houston Methodist and director of the Houston Research Institute.

Phase 2 data show zabopegdutide, a dual GLP-1/glucagon agonist, improved fibrosis and drove MASH resolution vs placebo at 48 weeks.

Latest News

Long-Term Budesonide Oral Suspension Therapy in EoE

Don't Miss a Beat: What Lp(a)HORIZON and ZEUS Teach About Clinical Trial Science

Transform-HTN: Lorundrostat Maintains Blood Pressure Reductions in Open-Label Extension

Rezpegaldesleukin's Early Treg Signal in AD: Emma Guttman-Yassky, MD

TYDAL-TIMI 78: MAR001 Reduces Fasting Triglyceride Through ANGPTL4 Inhibition